By Rishika Sadam and Kashish Tandon July 9 (Reuters) - India's Dr Reddy's Laboratories said on Thursday that supplies of its ...

The company expects shipments to resume by November, and has halves FY27 supply estimate, while saying patient safety and ...

When launching a drug as big as semaglutide, even as a generic, the market expectations are immense, and any fumble on the ...

India's Dr ​Reddy's Laboratories said on Thursday that supplies of its generic semaglutide would ‌remain unavailable in India ...

Despite the delay, Dr Reddy's maintained its broader financial outlook for fiscal 2027.

Dr Reddy's delayed Semaglutide supplies after certain batches failed quality specifications due to an API issue. The company ...

Multiple semaglutide makers have recalled batches or delayed supplies over quality concerns in India. Doctors are seeking transparent explanations as generics now account for most sales in the market.

Brokerage firm Jefferies, in a note dated July 1, stated that it is stretching its estimates for two key growth drivers for ...

Dr. Reddy’s Laboratories Ltd. will delay the commercial production of its generic Ozempic drug after it found an unspecified ...

Oluwaniyi Raji is a tech content specialist who covers consumer technology, software, and digital tools. He has published over 300 articles for outlets including BGR (Boy Genius Report), MakeUseOf, ...